Enveric Biosciences Inc (NASDAQ:ENVB) announced that the company's first four Patent Cooperation Treaty (PCT) applications for the tryptamine family of novel molecules have been published by the World Intellectual Property Organization (WIPO).
The Naples, Florida-based neuroscience company developing psychedelic-inspired mental health medicines said additional PCT patent applications are expected to be published over the coming months.
"Tryptamine represents the core structural motif for numerous intriguing therapeutically active agents such as the classic psychedelic molecules N, N-dimethyltryptamine (DMT), psilocybin, psilocin, and 5-MeO-DMT. Many of these molecules are being investigated worldwide as potential treatments for a broad range of psychiatric and neurologic disorders, including mood and anxiety disorders, post-traumatic stress disorder, cancer-related distress and more," Enveric chief medical officer Bob Dagher said in a statement.
READ: Enveric Biosciences files portfolio of patent applications for tryptamine derivatives
"These patent applications aim to protect Enveric's assets of new drug candidates and place our discovery engine at the forefront of bringing forward innovative psychiatric and neurologic therapeutics of the future," he added.
Tryptamine is a classic psychedelic molecule that binds to and activates serotonin and other receptors in the brain. The tryptamine class includes psilocybin, psilocin, and dimethyltryptamine (DMT), which are naturally occurring psychedelics that are currently under intense study for therapeutic applications.
Based on recent and emerging data, Enveric believes this class of molecules may have the potential to produce “rapid, profound, and long-lasting benefits” for a broad range of indications.
The published PCT patent applications protecting Enveric's novel tryptamine-derived molecules, as well as the Written Opinion of the International Searching Authority for each application, are available for review on the WIPO website.
Enveric's robust pipeline supports drug development from the clinic to commercialization for millions of patients in need around the world suffering from conditions that include cancer-related distress, post-traumatic stress disorder (PTSD) and more.
Contact the author Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive